{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:36:35Z","timestamp":1780641395710,"version":"3.54.1"},"reference-count":32,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Psoriasis is a chronic inflammatory skin disease that may have a significant impact on patients\u2019 quality of life. Alongside clinical scores, treatment goals include improvements in patients\u2019 quality of life, divided into its social, working and psychosocial life aspects. Indeed, psychological impairment should always be considered in the management of moderate-to-severe psoriasis. Tildrakizumab, an anti-IL-23, is approved for the management of moderate-to-severe psoriasis. Both clinical trials and real-life studies show its efficacy and safety; however, no studies have evaluated how tildrakizumab may improve different domains of quality of life, including physical, psychological, and social aspects of patients\u2019 quality of life. The objective was to evaluate the effectiveness of tildrakizumab in the management of moderate-to-severe psoriasis, focusing on the impact on all domains of patients\u2019 quality of life. Methods: A 28-week multicenter, real-life, retrospective study was performed enrolling patients affected by moderate-to-severe psoriasis undergoing treatment with tildrakizumab. PASI and DLQI were evaluated at each follow-up (W16, W28). A sub-analysis of each DLQI question evaluated different domains of quality of life, including physical, psychological, and social aspects of patients\u2019 quality-of-life. Results: A total of 62 patients were enrolled. At week 28, 97.1%, 85.7%, and 54.3% of patients achieved PASI75, PASI90, and PASI100, respectively. DLQI showed a significant reduction from baseline (20.3 \u00b1 5.5) to week 28 (0.9 \u00b1 2.2, p &lt; 0.0001), with up to 82.9% achieving DLQI &lt; 1. Sub-analysis of each question (Q1\u2013Q10) showed a reduction in the value of each answer from baseline to week 28. Conclusions: The results confirm tildrakizumab as an effective and safe treatment in real life, positively affecting all domains of quality of life, with significant impact already appreciable at week 16 of follow-up.<\/jats:p>","DOI":"10.3390\/jcm14010223","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T10:32:26Z","timestamp":1735813946000},"page":"223","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains\u2014Should Psychosocial Life Impairment Be Considered a Comorbidity?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-1331","authenticated-orcid":false,"given":"Gaetano","family":"Licata","sequence":"first","affiliation":[{"name":"Dermatology Unit, San Antonio Abate Hospital, 91016 Trapani, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-2443","authenticated-orcid":false,"given":"Eugenia Veronica","family":"Di Brizzi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Castelli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Ospedale Koelliker, 10024 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Giuffrida","sequence":"additional","affiliation":[{"name":"Dermatology Unit, A.O.U. Policlinico \u201cG. Rodolico\u2013S. Marco\u201d, 95100 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Stroppiana","sequence":"additional","affiliation":[{"name":"Dermatology Unit, A.O. Citt\u00e0 della Salute e della Scienza, 10024 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9504-5882","authenticated-orcid":false,"given":"Annunziata","family":"Dattola","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, 00042 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8755-9178","authenticated-orcid":false,"given":"Antonio Giovanni","family":"Richetta","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, 00042 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"De Col","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Palasalute ASL 1, 18100 Imperia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Peila","sequence":"additional","affiliation":[{"name":"Dermatology Unit, ASL TO 4, 10081 Castellamonte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Siliquini","sequence":"additional","affiliation":[{"name":"Dermatology Unit, A.O. Citt\u00e0 della Salute e della Scienza, 10024 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Solaroli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Ospedale Koelliker, 10024 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zanetta","sequence":"additional","affiliation":[{"name":"Dermatology Unit, ASL Stresa, 28838 Stresa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Cerulli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Ospedale S. Maria della Misericordia, 06121 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5308-686X","authenticated-orcid":false,"given":"Giovanna","family":"Galdo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Ospedale S. Giuseppe Moscati, 83100 Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Giordano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, A.O.U. Sant\u2019Andrea, 00042 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Faure","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Policlinico di Milano Ospedale Maggiore Fondazione IRCCS Ca\u2019, 18001 Granada, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Papaianni","sequence":"additional","affiliation":[{"name":"Dermatology Unit, A.O.U. P. \u201cG. Martino\u201d, 98121 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Pertusi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, P.O. Sant\u2019Andrea, 13100 Vercelli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Uzzauto","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Ospedale Tortora, 84016 Pagani, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Policlinico di Bari\u2013A.O.U. Consorziale Policlinico, 70100 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Zichichi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, San Antonio Abate Hospital, 91016 Trapani, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/jdv.15339","article-title":"Severity, heterogeneity and systemic inflammation in psoriasis","volume":"33","author":"Christophers","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-4632.2010.04844.x","article-title":"Stress and quality of life in psoriasis: An update","volume":"50","author":"Basavaraj","year":"2011","journal-title":"Int. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"109853","DOI":"10.1016\/j.mehy.2020.109853","article-title":"May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?","volume":"143","author":"Marasca","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Karampinis, E., Papadopoulou, M.-M., Chaidaki, K., Georgopoulou, K.-E., Magaliou, S., Roussaki Schulze, A.V., Bogdanos, D.P., and Zafiriou, E. (2024). Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters. Vaccines, 12.","DOI":"10.3390\/vaccines12020178"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1111\/jdv.16476","article-title":"Face the COVID-19 emergency: Measures applied in an Italian Dermatologic Clinic","volume":"34","author":"Marasca","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e15941","DOI":"10.1111\/dth.15941","article-title":"Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real-life study","volume":"35","author":"Ruggiero","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s13555-024-01190-4","article-title":"Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States","volume":"14","author":"Greiling","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Prignano, F., Brunasso, A.M.G., Fabbrocini, G., Argenziano, G., Bardazzi, F., Borroni, R.G., Burlando, M., Cagni, A.E., Campione, E., and Cinotti, E. (2022). Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102801"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/14712598.2022.1988566","article-title":"Tildrakizumab for treatment of moderate to severe psoriasis: An expert opinion of efficacy, safety, and use in special populations","volume":"22","author":"Galluzzo","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_11","unstructured":"European Medicines Agency (2024, June 14). Ilumetri (Tildrakizumab): Summary of Product Characteristics, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ilumetri-epar-product-information_en.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/jdv.15400","article-title":"Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: Pooled analysis of three randomized controlled trials at weeks 12 and 28","volume":"33","author":"Papp","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.36849\/jdd.7471","article-title":"Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study","volume":"22","author":"Heim","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2147\/CCID.S364640","article-title":"Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2147\/CCID.S402183","article-title":"Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study","volume":"16","author":"Ruggiero","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/jdv.14451","article-title":"Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis","volume":"31","author":"Amin","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Megna, M., Ruggiero, A., Battista, T., Marano, L., Cacciapuoti, S., and Potestio, L. (2023). Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093233"},{"key":"ref_18","first-page":"230","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet 2017, 390, 276\u2013288; Erratum in Lancet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","article-title":"Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: Results from an Italian 28-week retrospective study","volume":"33","author":"Megna","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Campione, E., Lambiase, S., Gaeta Shumak, R., Galluzzo, M., Lanna, C., Costanza, G., Borselli, C., Artosi, F., Cosio, T., and Tofani, L. (2023). A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040526"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/jdv.18594","article-title":"Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis)","volume":"37","author":"Narcisi","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"516","DOI":"10.47102\/annals-acadmedsg.V47N12p516","article-title":"Psychological Profile of Patients with Psoriasis","volume":"47","author":"Lim","year":"2018","journal-title":"Ann. Acad. Med. Singap."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1684\/ejd.2020.3768","article-title":"Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: Results from a large-scale survey in routine care","volume":"30","author":"Augustin","year":"2020","journal-title":"Eur. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Jankowiak, B., Krajewska-Ku\u0142ak, E., Jakoniuk, M., and Khvorik, D.F. (2023). Stigmatization among Patients with Plaque Psoriasis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196425"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s10880-018-9580-9","article-title":"Psychological Distress, Alexithymia and Alcohol Misuse in Patients with Psoriasis: A Cross-Sectional Study","volume":"26","author":"Founta","year":"2019","journal-title":"J. Clin. Psychol. Med. Settings"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1365-2230.2001.00834.x","article-title":"Psychological influences in psoriasis","volume":"26","author":"Griffiths","year":"2001","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13555-014-0043-4","article-title":"Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy","volume":"4","author":"Poulin","year":"2014","journal-title":"Dermatol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.17219\/acem\/69804","article-title":"The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment","volume":"26","author":"Reich","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2340\/00015555-1237","article-title":"Patients' visual analogue scale: A useful method for assessing psoriasis severity","volume":"92","author":"Stenberg","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/jdv.15862","article-title":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials","volume":"33","author":"Blauvelt","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e060536","DOI":"10.1136\/bmjopen-2021-060536","article-title":"Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: Protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)","volume":"13","author":"Augustin","year":"2023","journal-title":"BMJ Open."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1111\/jdv.19229","article-title":"Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice","volume":"37","author":"Costanzo","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/1\/223\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:22:06Z","timestamp":1759918926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/1\/223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["jcm14010223"],"URL":"https:\/\/doi.org\/10.3390\/jcm14010223","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]}}}